Date: 2017-09-01
Type of information: Product acquisition
Compound: immuno-oncology assets
Company: Oncurious (Belgium) VIB (Belgium)
Therapeutic area: Cancer - Oncology
Type agreement: product acquisition
Action mechanism: immunotherapy product
Disease:
Details:
- • On September 1, 2017, Oncurious announced that it has
reached principle agreement with VIB to acquire exclusive licences to a portfolio of five next generation immuno-oncology assets, based on seminal work originating from the VIB-KU Leuven labs of Massimiliano Mazzone and Gabriele Bergers, and from the VIB-VUB lab of Jo Van Ginderachter. VIB Discovery Sciences will take the lead in the pre-clinical development of these new projects.
Financial terms:
- As part of this agreement, VIB will increase its stake in Oncurious, with ThromboGenics remaining the majority shareholder. VIB will also receive a royalty on future sales of any of these assets. ThromboGenics invests an additional €2.1 million in Oncurious.
Latest news:
Is general: Yes
